Search Clinical Trials in the European Union

Duration
>20 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 140 trials

Atrial Fibrillation: Abelacimab Treatment Study

We are studying whether abelacimab can help high-risk patients with atrial fibrillation who cannot take oral blood thinners. The goal is to see if it reduces the risk of strokes and other serious complications compared to a placebo.

Atrial Fibrillation>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Pleural Mesothelioma: Volrustomig with Carboplatin and Pemetrexed

We are studying a new treatment combination for patients with unresectable pleural mesothelioma. The goal is to see if it works better than current standard care options.

Unresectable Pleural Mesothelioma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Melanoma Treatment: ABP 206 vs. OPDIVO

We are evaluating a new treatment, ABP 206, for patients with advanced melanoma who have not been treated before. The study aims to see how well it works and how safe it is compared to OPDIVO.

Metastatic Melanoma>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Efepoetin Alfa for Anemia in Chronic Kidney Disease on Dialysis

We are studying whether efepoetin alfa can effectively manage anemia in patients with chronic kidney disease on dialysis, compared to another treatment. This trial will also assess safety and quality of life for participants.

Anemia of Chronic Disease1-2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyNephrology

Systemic Lupus Erythematosus: Upadacitinib Study

We are investigating whether the oral medication upadacitinib can improve symptoms in adults with moderate to severe systemic lupus erythematosus. The study will also monitor its safety over time compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementRheumatology

Locally Advanced NSCLC: Alectinib vs. Durvalumab

We are studying whether alectinib or entrectinib is more effective than durvalumab for patients with advanced non-small cell lung cancer who have not progressed after initial treatment. The trial also looks at quality of life and safety for participants.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Urothelial Cancer: BT8009 Treatment Study

We are investigating whether the new drug BT8009, alone or with pembrolizumab, can help patients with advanced urothelial cancer live longer and respond better than standard chemotherapy.

Locally Advanced or Metastatic Urothelial Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyUrology

Fetal and Neonatal Alloimmune Thrombocytopenia: Nipocalimab Study

We are testing nipocalimab in pregnant individuals at risk of FNAIT to see if it can lower the chances of severe complications for the baby. This study compares the treatment to a placebo to evaluate its effectiveness.

Neonatal Alloimmune Thrombocytopenia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsInfectious Diseases

Multiple Sclerosis: Frexalimab vs. Teriflunomide

We are studying a new medication, frexalimab, for adults with relapsing forms of multiple sclerosis. The goal is to see if it works better than teriflunomide in reducing relapses and improving quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Frexalimab for Nonrelapsing Secondary Progressive Multiple Sclerosis

We are studying whether frexalimab can help delay disability progression in adults with nonrelapsing secondary progressive multiple sclerosis. The trial also examines its effects on quality of life and safety.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Secukinumab: Long-Term Safety Study

We are evaluating the long-term safety of Secukinumab for patients who have previously participated in a related study. This trial will help us understand any potential side effects of continued treatment.

Psoriatic ArthritisAnkylosing SpondylitisNon-radiographic Axial Spondyloarthritis>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicineRheumatology

Chronic Lymphocytic Leukemia: Venetoclax and Obinutuzumab Study

We are assessing the effectiveness and safety of a combination treatment for adults with recurring chronic lymphocytic leukemia. This study aims to understand how well the treatment works and what side effects may occur.

Recurrent Chronic Lymphocytic Leukemia1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Choroidal Melanoma: Belzupacap Sarotalocan Treatment

We are studying a new treatment for people with primary indeterminate lesions or small choroidal melanoma. The goal is to see if it is more effective and safe compared to a placebo.

Choroidal Melanoma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncologyOphthalmology

Atopic Dermatitis in Children: Upadacitinib vs. Dupilumab

We are studying whether upadacitinib is as safe and effective as dupilumab for children aged 2 to under 12 with moderate to severe atopic dermatitis. This trial aims to find better treatment options for young patients.

Atopic Dermatitis>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatologyPediatrics

Cushing’s Disease: Lu AG13909 Treatment Study

We are investigating a new medication, Lu AG13909, for adults with Cushing’s disease to see how it affects cortisol levels and its safety. This trial aims to improve understanding of this rare condition and its treatment options.

Cushing's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Cystic Fibrosis: VX-522 Treatment Study

We are testing a new medication, VX-522, for adults with cystic fibrosis who do not respond to current treatments. The study will help us understand its safety and effectiveness compared to existing therapies.

Cystic Fibrosis6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPulmonology

Cutaneous Lupus Erythematosus: Litifilimab Injections

We are studying the long-term safety and effects of Litifilimab injections for adults with active cutaneous lupus erythematosus who have not responded to other treatments. This research aims to see if it can improve symptoms and overall quality of life.

Skin Lupus (Cutaneous Lupus Erythematosus)>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Bomedemstat vs Best Available Therapy for Essential Thrombocythemia

We are studying a new treatment for patients with essential thrombocythemia who haven't responded to hydroxyurea. The trial aims to see if bomedemstat is safer and more effective than current therapies.

Essential Thrombocythemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Advanced NSCLC: EXL-01 with Nivolumab

We are studying the combination of EXL-01 and nivolumab for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy. The trial aims to evaluate how well this combination works and its safety.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Chronic Lymphocytic Leukemia: Venetoclax and Acalabrutinib Treatment

We are studying a combination of venetoclax and acalabrutinib for patients with CLL who have relapsed after previous treatment. The goal is to see if this combination can help achieve better disease control and improve quality of life.

Chronic Lymphocytic LeukemiaPatients with Relapsed CLL>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology